UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported): May 11, 2017
ZIOPHARM Oncology, Inc.
(Exact Name of Registrant as Specified in Charter)
| | | | |
| Delaware | | 001-33038 | | 84-1475642 |
(State or Other Jurisdiction of Incorporation) | | (Commission File Number) | | (IRS Employer Identification No.) |
| | | | |
One First Avenue, Parris Building 34, Navy Yard Plaza Boston, Massachusetts | | 02129 |
| (Address of Principal Executive Offices) | | (Zip Code) |
(617)259-1970
(Registrant’s telephone number, including area code)
Not applicable
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if theForm 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425). |
| ☐ | Soliciting material pursuant toRule 14a-12 under the Exchange Act(17 CFR 240.14a-12). |
| ☐ | Pre-commencement communications pursuant toRule 14d-2(b) under the Exchange Act (17 CFR240.14d-2(b)). |
| ☐ | Pre-commencement communications pursuant toRule 13e-4(c) under the Exchange Act (17 CFR240.13e-4(c)). |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act (17 CFR 230.405) or Rule12b-2 of the Exchange Act (17 CFR240.12b-2).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
On May 11, 2017, ZIOPHARM Oncology, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Guggenheim Securities, LLC, as sole underwriter, relating to the issuance and sale of 9,708,738 shares of the Company’s common stock (the “Offering”) at an offering price of $5.15 per share. The gross proceeds to the Company from the Offering are expected to be $50.0 million before deducting the underwriting discounts and commissions and offering expenses payable by the Company. The offering is scheduled to close on or about May 16, 2017, subject to customary closing conditions.
The Offering is being made pursuant to the Company’s effective shelf registration statement on FormS-3ASR (Registration StatementNo. 333-201826), previously filed with the Securities and Exchange Commission (“SEC”). The Offering is being made only by means of a prospectus supplement and an accompanying prospectus.
The Underwriting Agreement contains customary representations, warranties, covenants and agreements by the Company, indemnification obligations of the Company and the underwriters, including for liabilities under the Securities Act of 1933, as amended, other obligations of the parties and termination provisions. The representations, warranties and covenants contained in the Underwriting Agreement were made only for purposes of such agreement and as of specific dates, were solely for the benefit of the parties to the Underwriting Agreement, and may be subject to limitations agreed upon by the contracting parties.
The Underwriting Agreement is filed as Exhibit 1.1 hereto and is incorporated herein by reference. The foregoing description of the terms of the Underwriting Agreement is qualified in its entirety by reference to such exhibit. A copy of the opinion of Cooley LLP relating to the legality of the issuance and sale of the shares in the Offering is attached as Exhibit 5.1 hereto.
On May 12, 2017, the Company issued a press release announcing the pricing of the Offering. A copy of this press release is attached as Exhibit 99.1 hereto.
| Item 9.01 | Financial Statements and Exhibits |
| | |
Exhibit
No. | | Description |
| |
| 1.1 | | Underwriting Agreement by and between Guggenheim Securities, LLC and the Company dated May 11, 2017. |
| |
| 5.1 | | Opinion of Cooley LLP. |
| |
| 23.1 | | Consent of Cooley LLP (included in Exhibit 5.1). |
| |
| 99.1 | | Press Release dated May 12, 2017. |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| | | | | | | | |
| | | | ZIOPHARM Oncology, Inc. |
| | | |
| | | | By: | | /s/ Kevin G. Lafond |
| Date: May 12, 2017 | | | | | | Name: | | Kevin G. Lafond |
| | | | | | Title: | | Vice President, Chief Accounting Officer and Treasurer |
INDEX OF EXHIBITS
| | |
Exhibit
No. | | Description |
| |
| 1.1 | | Underwriting Agreement by and between Guggenheim Securities, LLC and the Company dated May 11, 2017. |
| |
| 5.1 | | Opinion of Cooley LLP. |
| |
| 23.1 | | Consent of Cooley LLP (included in Exhibit 5.1). |
| |
| 99.1 | | Press Release dated May 12, 2017. |
